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Abstract
Introduction Accumulation of fatty acids and neutral lipids in
nonadipose tissues is cytotoxic. We recently showed that
ERBB2-positive breast cancer cells produce significantly high
amounts of fats, because of overexpression of the peroxisome
proliferator-activated receptor (PPAR)γ-binding protein and the
nuclear receptor NR1D1 (nuclear receptor subfamily 1, group
D, member 1; Rev-erbα). These genes upregulate de novo fatty
acid synthesis, which is a critical pathway for the energy
production and survival of these cells. NR1D1 and PPARγ-
binding protein are functionally related to PPARγ, a well
established positive regulator of adipogenesis and lipid storage.
Methods The effects of GW9662 and exogenously added
palmitate on breast cells (BT474, MDA-MB-361, MCF-7, and
human mammary epithelial cells) in monolayer culture were
assessed. Mass spectrometric quantitation of fatty acids and
fluorescence-based high content microscopy assays of cell
growth, apoptosis, triglyceride storage and reactive oxygen
species production were used.
Results ERBB2-positive breast cancer cells are more sensitive
to inhibition of PPARγ activity by the antagonist GW9662.
PPARγ inhibition results in increased levels of total fats in the
cells, mostly because of increased amounts of palmitic and
stearic unsaturated acids. Administration of exogenous
palmitate is lethal to ERBB2-positive but not to ERBB2-negative
cells. GW9662 exacerbates the effects of palmitate addition on
BT474 and MDA-MB-361 cells, but it has no significant effect
on MCF-7 and human mammary epithelial cells. Palmitate
administration results in a fivefold to tenfold greater increase in
fat stores in ERBB2-negative cells compared with ERBB2-
positive cells, which suggests that the ERBB2-positive cells
have maximized their ability to store fats and that additional
palmitate is toxic to these cells. Both PPARγ inhibition and
palmitate administration result in increased reactive oxygen
species production in BT474 cells. The cell death that results
from this treatment can be counteracted by the antioxidant N-
acetyl cysteine.
Conclusions Our findings indicate that PPARγ activity enables
ERBB2-positive breast cancer cells, which produce high levels
of fat, to convert fatty acids to triglycerides, allowing these cells
to avert the cell death that results from lipotoxicity. Endogenous
palmitate toxicity represents a genetically based property of
ERBB2-positive breast cancer that can be exploited for
therapeutic intervention.
Introduction
Amplification of the ERBB2 oncogene is one of the most clin-
ically relevant genetic changes in breast cancer and occurs in
10% to 34% of breast cancer cases. ERBB2 overexpression
is a significant predictor of both overall survival and time to
relapse [1]. The association of ERBB2 amplification withPage 1 of 11
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has made ERBB2 an attractive therapeutic target. Trastuzu-
mab, a human monoclonal antibody targeted against the extra-
cellular domain of ERBB2, was widely hailed as the first next
generation cancer therapy when it was introduced for the
treatment of estrogen receptor-negative breast cancer. Its
success has been modest. When used as single-agent ther-
apy in patients with metastatic ERBB2-positive breast cancer,
response rates ranging from 11% to 26% have been
observed. Because a relatively large proportion of patients do
not benefit from ERBB2-targeted therapy, it is likely that fac-
tors in addition to ERBB2 itself must influence the response of
these tumors to this therapy. Recently, an RNA interference
screen identified regulators of fat metabolism (including the
peroxisome proliferator-activated receptor [PPAR]γ-binding
protein [PBP] and the nuclear receptor NR1D1 [nuclear
receptor subfamily 1, group D, member 1], a PPARγ target
protein) as being relevant to the survival specifically of
ERBB2-positive breast cancer cells, but not that of other
breast cancer cells or normal mammary epithelial cells (Kour-
tidis A, Carkner RD, Eifert C, Brosnan MJ, Conklin DS; unpub-
lished data). Both genes reside on the ERBB2 amplicon and
are transcriptional regulators that positively affect expression
of genes such as FASN (fatty acid synthase), ACLY (ATP cit-
rate lyase) and ACACA (acetyl-coenzyme A carboxylase
alpha), which are the three major enzymes of de novo fatty acid
synthesis (Kourtidis A, Carkner RD, Eifert C, Brosnan MJ, Con-
klin DS; unpublished data). As a result, ERBB2-positive breast
cancer cells contain significantly higher amounts of cellular
fats, as compared with other breast cancer cell lines or normal
cells, because of concomitant overexpression of NR1D1 and
PBP genes (Kourtidis A, Carkner RD, Eifert C, Brosnan MJ,
Conklin DS; unpublished data) [2].
The end product of de novo fatty acid synthesis, namely palmi-
tate, and other saturated fatty acids like it, are toxic to cells.
Palmitate has been shown to generate a variety of apoptotic
signals [3,4]. In some cases these involve the synthesis of
ceramide [5,6], whereas in others reactive oxygen species
(ROS) are produced [3,7]. Studies conducted in a variety of
cell types, including breast cancer cell lines [8,9], suggest that
this lipotoxicity is specific for saturated fatty acids such as
palmitate. Triglyceride accumulation in nonadipose cells repre-
sents a cellular defense mechanism against lipotoxicity [10].
Because exogenous unsaturated fatty acids have an impact on
this process, it may represent a mechanism for effects of diet
on cancer etiology.
Both PBP and NR1D1 are functionally related to PPARγ
[11,12]. PPARγ expression is also higher in ERBB2-positive
breast cancer cells [13]. These cells were more sensitive to
inhibition of PPARγ with antagonists such as GW9662 and
T0070907, as compared with other types of breast cancer
cells or normal mammary epithelial cells (Kourtidis A, Carkner
RD, Eifert C, Brosnan MJ, Conklin DS; unpublished data).
PPARγ inhibition in ERBB2-positive breast cancer cells
resulted in cell death and apoptosis, similar to the effects of
PBP and NR1D1 inhibition (Kourtidis A, Carkner RD, Eifert C,
Brosnan MJ, Conklin DS; unpublished data). PPARγ is a major
regulator of adipogenesis and lipid homeostasis [14]. We
sought to examine the reasons for the dependence of ERBB2-
positive breast cancer cells on PPARγ for survival. In this con-
text, we identified palmitate-induced lipotoxicity as a main
effect of PPARγ inhibition in ERBB2-positive breast cancer
cells.
Materials and methods
Cell culture and chemicals
Breast cancer cell lines BT474, MCF-7 and MDA-MB-361
were obtained from the American Type Culture Collection
(Manassas, VA, USA). Human mammary epithelial cells
(HMECs) were obtained from Cambrex (East Rutherford, NJ,
USA). BT474 and MCF-7 cells were cultured in Dulbecco's
modified Eagle's medium (Hyclone, Logan, UT, USA) supple-
mented with 10% fetal bovine serum (Hyclone) and 100 U/μl
penicillin-streptomycin (Cellgro, Herndon, VA, USA); BT474
medium was also supplemented with ITS (insulin, transferring
and selenium; Cellgro). MDA-MB-361 were cultured in RPMI-
1640 (Hyclone) supplemented with 20% fetal bovine serum
and 100 U/μl penicillin-streptomycin. HMECs were cultured in
mammary epithelial growth medium (Cambrex). The PPARγ
antagonist GW9662, the fatty acid palmitate, and the cera-
mide synthesis inhibitor fumonisin B1 were obtained from
Sigma-Aldrich (St. Louis, MO, USA).
Cell viability: proliferation assays
Cell viability after small hairpin RNA transfection or chemical
treatments was assessed live cell counts after trypsinization
and trypan blue staining using a hemocytometer. For high-
throughput experiments, cells grown on 96-well plates were
washed once with 1× phosphate-buffered saline (PBS), fixed
with 2.5% formaldehyde, stained with Hoechst 33342 (Molec-
ular Probes-Invitrogen, Carlsbad, CA, USA) and analyzed with
an In Cell Analyzer 1000 (GE Healthcare, Piscataway, NJ,
USA) high-content imaging system; cell counts and statistics
were performed using In Cell Investgator 3.4 software (GE
Healthcare).
Reverse transcription polymerase chain reaction
Total RNA was extracted from cells using TRizol (Invitrogen,
Carlsbad, CA, USA). cDNA was synthesized by reverse tran-
scription of 2 μg of RNA in a 20 μl reaction using Moloney
murine leukemia virus reverse transcriptase (Promega, Madi-
son, WI, USA) at 42°C for 1 hour. PCR reactions were per-
formed by using standard Taq polymerase (Fisher
BioReagents, Fairlawn, NJ, USA) with the following primer
pairs (forward and reverse, respectively): PPARγ, 5'-AGCCT-
CATGAAGAGCCTTCCA-3' and 5'-ACCCTTGCATCCT-
TCACAAGC-3'; fatty acid binding protein 4 (FABP4; aP2), 5'-
GCATGGCCAAACCTAACATGAT-3' and 5'-CCT-Page 2 of 11
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(HSL), 5'-TACAAACGCAACGAGACAGGC-3' and 5'-TGT-
GATCCGCTCAAACTCAGC-3'; adipose tryglyceride lipase
(ATGL), 5'-AGCTCATCCAGGCCAATGTCT-3' and 5'-
GGTTGTCTGAAATGCCACCAT-3'; carnitine palmitoyltrans-
ferase 1 (CPT-1), 5'-TCACATTCAGGCAGCAAGAGC-3'
and 5'-AATCGTGGATCCCAAAAGACG-3'; and glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH), 5'-GCAAAT-
TCCATGGCACCGT-3' and 5'-TCGCCCCACTTGATTTTG
G-3'.
After the initial denaturation step (95°C for 3 minutes), PCR
reactions consisted of 30 to 35 cycles of a 95°C step (15 sec-
onds), a 52 to 55°C step (15 seconds), and a 72°C step (20
seconds), followed by a final elongation step at 72°C (5 min-
utes). PCR products were separated on 2% agarose-ethidium
bromide gels. For quantitative determination of PCR product,
a real-time reverse transcription PCR (RT-PCR) was per-
formed on an ABI PRISM 7900 HT Sequence Detection Sys-
tem (Applied Biosystems, Foster City, CA, USA), using SYBR
Green PCR Master Mix (Applied Biosystems). Primer pairs
were the same as those used in regular RT-PCR. PCR reac-
tions consisted of an initial incubation at 95°C (2.5 minutes)
and 40 cycles of a 95°C step (15 seconds) and a 60°C step
(60 seconds). Product levels were calculated after normaliza-
tion with GAPDH or β-actin controls.
Immunofluoresence
Immunofluoresence was performed on cells grown and
treated either in 96-well plates or on cover slips in 24-well
plates. In all cases, cells were fixed after treatment with 2.5%
formaldehyde, washed with 1× PBS, permeabilized with 0.1%
Triton-X 100 (Fisher Chemicals, Fairlawn, NJ, USA), blocked
with 3% normal goat serum (Sigma-Aldrich), incubated with a
1:50 to 1:200 dilution of the primary antibody, washed with 1×
PBS, incubated with a 1:800 dilution of the secondary anti-
body, washed again with 1× PBS, and finally stained with
Hoechst 33342 (Molecular Probes-Invitrogen). Cells stained
on 96-well plates were imaged using the In Cell Analyzer 1000
(GE Healthcare) and signal measurements and statistics were
performed by the In Cell Investigator 3.4 software (GE Health-
care). Cells immunostained on cover slips were imaged by
using a Leica TCS SP5 confocal microscope system (Leica
Microsystems Inc., Bannockburn, IL, USA). Antibodies used
were anti-activated Bax (6A7; BD Pharmingen, San Jose, CA,
USA) and Alexa Fluor 568 goat anti-rabbit IgG (#A-11011;
Invitrogen).
Metabolic assays
For detection of neutral fat stores, cells were grown on 96-well
plates, fixed with 2.5% formaldehyde, washed with 1× PBS,
stained with 10 μg/ml 4,4-difluoro-1,3,5,7,8-pentamethyl-4-
bora-3a,4a-diaza-s-indacene (BODIPY 493/503; Molecular
Probes), and counter-stained with Hoechst 33342 (Molecular
Probes) for nuclei identification. Cells were imaged using the
In Cell Analyzer 1000 and pictures were analyzed using the In
Cell Investigator 3.4 software.
For fatty acid detection and quantification, total cellular lipids
were extracted in accordance with a procedure described pre-
viously [15]. Briefly, approximately 107 cells were pelleted and
re-suspended in 3 ml chloroform:methanol (1:2) weight/
0.05% butylated hydroxytoluene (BHT) to extract lipids. To
monitor the recovery of fatty acids, 100 μg of heptadecanoic
acid was added to each sample, before lipid extraction. Sam-
ples were centrifuged to remove cellular debris and chloro-
form and distilled water was added to form a biphasic solution.
The two phases were separated by centrifugation and organic
phases were transferred to a new tube and dried under nitro-
gen gas. Fats were then re-suspended in 250 μl toluene +
500 μl 1% sulfuric acid in methanol and incubated at 50°C
overnight under nitrogen gas, followed by two steps of 1.25 ml
5% NaCl – 1.25 ml hexane extraction. Hexane extractions
were combined, washed with 1.0 ml 2% NaHCO3, run
through Na2SO4 columns, and dried under nitrogen gas. The
fatty acid methyl esters were re-suspended in 1.0 ml methyl
acetate and were analyzed by gas chromatography/mass
spectrometry using an Agilent 6890 series gas chromato-
graph (Agilent Technologies Inc., Santa Clara, CA, USA)
equipped with a 5873 mass-selective detector. Part of the
extraction was used for quantification of total and individual
fatty acids under mass spectrometry and part for thin layer
chromatography separation of triglycerides by a toluene-
based system.
Reactive oxygen species assay
O2- generation was measured by using hydroethidine (Molec-
ular Probes-Invitrogen, Carlsbad, CA, USA). Cells were incu-
bated with a final concentration of 10 μmol/l of the dye for 30
minutes, and then fixed with 2.5% formaldehyde, stained with
Hoechst 33342 and imaged with an In Cell Analyzer 1000.
The hydroethidine signal was quantified using the In Cell
Investigator 3.4 software.
Statistical analysis
The Student's two-tailed t-test was employed for the calcula-
tion of P values.
Results
PPARγ inhibition results in increased levels of fats
Inhibition of PPARγ transcriptional activity using the antagonist
GW9662 resulted in increased cell death, specifically of the
ERBB2-positive BT474 and MDA-MB-361 breast cancer
cells, in a time-dependent and dosage-dependent manner, but
not of the ERBB2-negative MCF-7 or normal HMECs (Figure
1a). PPARγ is a major adipogenesis regulator, and therefore
we examined cells for changes in fat content. Because we
were primarily interested in learning why the ERBB2-positive
cells were sensitive to treatment with PPARγ antagonists
whereas the EBRB2-negative cells were relatively resistant,Page 3 of 11
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Figure 1
PPARγ inhibition results in ERBB2-positive cancer cell death and increased levels of fats. (a) Cell counts of BT474, MDA-MB-361, MCF-7, and 
human mammary epithelial cell (HMEC) cells treated with vehicle, 5, 10, and 20 μmol/l of the peroxisome proliferators-activated receptor (PPAR)γ 
antagonist GW9662 for 24, 48, and 72 hours. Results are presented as percentage of control (vehicle). Error bars indicate the standard deviation 
from three individual experiments. ***P < 0.003, **P < 0.05. (b) Quantification (nmol/100,000 cells) of total cellular fats from BT474 and MCF-7 
whole cell extracts by mass spectrometry after treatment with vehicle or 10 μmol/l of GW9662. Error bars indicate the standard deviation from two 
experiments. **P = 0.01, *P = 0.3). (c) Quantification of neutral fat stores of BT474 and MCF-7 cells treated with vehicle or 10 μmol/l of GW9662 
by using the BODIPY 493/503 lipid probe staining. Error bars indicate the standard deviation from three individual experiments. **P = 0.05, *P = 
0.1. (d) RT-PCR of BT474 cells treated with vehicle, 10, or 20 μmol/l of GW9662. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was 
used as control. (e) Quantification (in nmol/100,000 cells) by mass spectrometry of palmitic, palmitoleic, stearic, and oleic fatty acids from BT474 
and MCF-7 whole cell extracts after treatment with vehicle or 10 μmol/l of GW9662. Error bars indicate the standard deviation from two experi-
ments. **P < 0.05. aP2, fatty acid binding protein 4 (FABP4); ATGL, adipose tryglyceride lipase; CPT, carnitine palmitoyltransferase; HSL, hormone 
sensitive lipase.
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tive (BT474) and an ERBB2-negative cell line (MCF-7). Over-
all, BT474 cells contain twice the amount of total fats (Figure
1b) and three times more stored triglycerides compared with
MCF-7 cells (Figure 1c). This is consistent with our previous
studies showing overexpression of NR1D1, PBP, and FASN,
causing higher fat content in ERBB2-positive cells (Kourtidis
A, Carkner RD, Eifert C, Brosnan MJ, Conklin DS; unpublished
data). In order to quantify the total amount of fats after PPARγ
inhibition, we used sublethal concentrations of GW9662,
because at higher concentrations extensive cell death occurs
(Figure 1a) preventing reliable measurement. Mass spectrom-
etry revealed a minor increase in the total amount of fats in
both cell lines (Figure 1b). A similar increase was observed in
triglyceride stores (Figure 1c). These findings were somewhat
surprising, because it was expected that inhibition of PPARγ
would lead to decreased fat levels.
To investigate the cause of the nearly steady levels of stored
fats, the message levels of PPARγ target genes related to trig-
lyceride degradation were examined. The major target of
PPARγ, namely fatty acid binding protein aP2 [16], was down-
regulated upon PPARγ inhibition, indicating that GW9662
effectively blocks PPARγ transcriptional activity (Figure 1d).
Interestingly, PPARγ mRNA itself was downregulated by the
GW9662 antagonist (Figure 1d). The two major lipases
involved in the breakdown of triglycerides, HSL and ATGL,
were downregulated upon use of GW9662 (Figure 1d), as
expected [17,18]. It has been shown that HSL, in order to
effectively continue triglyceride degradation, interacts with
aP2, which binds and removes fatty acids from lipid droplets
[19]. Therefore, the increase in triglyceride levels after down-
regulation of aP2 and HSL, as well as ATGL, is consistent with
attenuation of lipolysis. Furthermore, mRNA levels of carnitine
palmitoyltransferase 1, the key enzyme in fatty acid β-oxidation,
were not affected by GW9662 treatment, showing that fatty
acid degradation was not induced after PPARγ inhibition (Fig-
ure 1d). Taken together, these findings provide clues for the
observed lack of triglyceride degradation after PPARγ inhibi-
tion.
In order to examine levels of individual fatty acids, we examined
the fat content of the BT474 and MCF-7 cells by mass spec-
trometry. The results showed that that the higher fat levels
after PPARγ inhibition at sublethal concentrations of GW9662
(10 μmol/l) were primarily due to increased amounts of the sat-
urated palmitic and stearic fatty acids (increases of 1.7 and
1.6 nmol/100,00 cells, respectively; P < 0.05; Figure 1e).
These two fatty acids, together with the unsaturated palmito-
leic and oleic acids, comprised almost 80% of the total
amount of fats in the cells examined, with palmitate content
reaching about 30% (Figure 1b,e). The increase in palmitic
and stearic acids was also higher by 0.9 and 1.2 nmol/
100,000 cells, respectively, in BT474 cells compared with
MCF-7 cells (Figure 1e). Therefore, inhibition of PPARγ leads
to increased levels of fats, mainly due to the increased produc-
tion of palmitate.
Exogenous administration of palmitate is toxic 
specifically for ERBB2-positive cells
The end product of de novo fatty acid synthesis, palmitate, is
toxic to cells. The relatively high levels of activity of the fatty
acid synthesis pathway in the ERBB2-positive breast cancer
cells are likely to require a mechanism for overcoming the toxic
effects of palmitate excess. PPARγ inhibition correlated with
increased palmitate content and cell death in BT474 cells.
Therefore, PPARγ activity in the highly fat-producing ERBB2-
positive cells may serve in the detoxification of cells from
palmitate excess, by affecting its storage as triglycerides. To
investigate whether excess palmitate could be the trigger of
cell death, cells were grown with 250, 500, and 750 μmol/l of
palmitate. BT474 and MDA-MB-361 cells were highly sensi-
tive to exogenously added palmitate, which caused cell death
in a dose-dependent manner, resulting after 72 hours in 1.5 to
1.8 times less cells than the initial population at 750 μmol/l
(Figure 2a). In contrast, palmitate only decreased proliferation
of MCF-7 cells and HMECs by 50% and 25%, respectively, at
the highest concentrations, without causing cell death (Figure
2b). Interestingly, whereas BT474 cells appear to have accu-
mulated about two to three times and MDA-MB-361 cells
about seven to eight times more triglycerides after treatment
with 500 to 750 μmol/l palmitate, MCF-7 cells were able to
increase their fat stores by 30 to 40 times and HMECs by 16
to 25 times under the same conditions, without any effect in
their viability (Figure 2b). The effect of palmitate treatment on
ERBB2-positive cells was exacerbated by simultaneous addi-
tion of GW9662, whereas the same treatments were without
effect on MCF-7 cell and HMEC viability (Figure 2c).
Further examination of the cause of BT474 cell death after
palmitate addition showed that this is due to increased apop-
tosis. Palmitate administration resulted in increased activated
Bax signal, in a dose-dependent manner (Figure 3a,b), which
was also further induced by GW9662 addition (Figure 3a,c).
Neither palmitate nor GW9662 addition resulted in Bax acti-
vation in MCF-7 cells or HMECs. The above findings support
the idea that ERBB2-positive cells have near toxic levels of
endogenously produced palmitate, which lead to apoptosis
when PPARγ activity is inhibited.
Peroxisome proliferator-activated receptor-γ inhibition 
and palmitate administration in ERBB2-positive cells 
result in reactive oxygen species production
It is well established that palmitate toxicity can be mediated by
ROS production. In studies conducted in Chinese hamster
ovary cells, intracellular palmitate accumulation induced apop-
tosis through generation of ROS [7]. To test whether PPARγ
blockade by GW9662 and palmitate toxicity in ERBB2-posi-
tive cells is due to ROS production, we used hydroethidine, an
O2- species fluorescent indicator, to monitor cells after thesePage 5 of 11
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fold increase in hydroethidine signal in BT474 cells and a sev-
enfold to 20-fold increase in MDA-MB-361 cells, when
administering 500 to 750 μmol/l of the fatty acid (Figure 4a,b).
Palmitate treatment did not result in increased hydroethidine
signal in MCF-7 cells at any concentration and induced only a
moderate increase in HMECs at the highest concentration
(Figure 4a,b). This increase in HMECs does not correlate with
cell death (Figure 2a) and produces only a modest increase in
activated Bax signal when compared with the activated Bax
increase observed in the BT474 and MDA-MB-361 cells
under these conditions (Figure 3b). Therefore, the moderate
increase of the hydroethidine signal in HMECs treated with
750 μmol/l palmitate is not suggestive of palmitate sensitivity
in these cells. GW9662 also resulted in an almost threefold
increase in hydroethidine signal in BT474 and twofold in MDA-
MB-361 cells, but not in MCF-7 cells or HMECs (Figure 4a,c).
Induction of O2- species in BT474 cells by palmitate was exac-
erbated by GW9662 addition (Figure 4a,c), consistent with
the similar exacerbation of apoptosis under the same condi-
tions (Figure 3c).
To determine whether ROS is the reason for cell death, BT474
and MDA-MB-361 cells were treated with GW9662 together
with the antioxidant N-acetyl-cysteine. N-acetyl-cysteine res-
cued cells from PPARγ inhibition, indicating that oxidative
damage caused by increased ROS is the reason for cell death
(Figure 5a). Another mediator of palmitate toxicity is ceramide
synthesis. To examine whether PPARγ inhibition results in
ceramide-mediated toxicity, BT474 and MDA-MB-361 cells
treated with GW9662 were simultaneously treated with the
ceramide synthesis inhibitor fumonisin B1. Fumonisin B1 only
Figure 2
Administration of exogenous palmitate is toxic specifically to ERBB2-positive cells. (a) BT474, MDA-MB-361, MCF-7 and human mammary epithe-
lial cell (HMEC) cells treated with 250, 500, and 750 μmol/l palmitate for 72 hours. Cell counts are shown as percentage of seeded cell number at 
0 hours. Error bars indicate the standard deviation from three individual experiments). (b) Quantification of neutral fat stores of BT474, MDA-MB-
361, MCF-7, and HMEC cells treated with 250, 500, and 750 μmol/l palmitate for 72 hours by using the BODIPY 493/503 lipid probe staining. 
Error bars indicate the standard deviation from three individual experiments. (c) BT474, MDA-MB-361, MCF-7, and HMEC cells treated with 500 
μmol/l palmitate and/or 20 μmol/l GW9662 for 72 hours. Cell counts are shown as percentage of seeded cell number at 0 hours. Error bars indicate 
the standard deviation from three individual experiments. ***P < 0.0005, **P = 0.03.Page 6 of 11
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ated cell death (Figure 5b), indicating that palmitate toxicity
caused by PPARγ inhibition in BT474 cells is largely ceramide
indepedent. Therefore, PPARγ inhibition results in ROS pro-
duction that causes apoptosis in BT474 cells.
Discussion
ERBB2-positive cells possess significantly higher amounts of
tryglyceride stores than do other cell types (Kourtidis A, Cark-
ner RD, Eifert C, Brosnan MJ, Conklin DS; unpublished data;
Figure 1b–e). It has been shown that PBP and NR1D1 pro-
mote adipogenesis, and therefore fat storage, because of their
functional relationship with PPARγ (Kourtidis A, Carkner RD,
Eifert C, Brosnan MJ, Conklin DS; unpublished data) [11,12].
PPARγ activity is necessary for the viability specifically of
ERBB2-positive breast cancer cells, in a similar manner to
PBP and NR1D1 (Kourtidis A, unpublished data; Carkner RD,
Eifert C, Brosnan MJ, Conklin DS; Figure 1a). Our findings
indicate that apoptosis due to PPARγ inhibition is consistent
with endogenous palmitate toxicity. PPARγ enables ERBB2-
positive breast cancer cells to convert fatty acids to triglycer-
ides in order to avert lipotoxicity caused by the significantly
high levels of fats that these cells produce. The decreased
ability of BT474 and MDA-MB-361 cells to accumulate more
fats after exogenous supplementation of palmitate (Figure
2b,d) is in agreement with the idea that these cells have near
toxic levels of endogenously produced palmitate. Exogenous
palmitate that has no effects on MCF-7 cell or HMEC viability
is lethal to the ERBB2-positive cells. These results underscore
the importance of triglyceride accumulation as a cellular
Figure 3
Palmitate toxicity of ERBB2-positive cells is due to increased apoptosis. (a) Images of BT474, MDA-MB-361, MCF-7, and human mammary epithe-
lial cell (HMEC) cells stained for activated Bax signal that were treated with 500 or 750 μmol/l palmitate, 20 μmol/l GW9662, or 500 μmol/l palmi-
tate plus 20 μmol/l GW9662, all for 72 hours. Hoechst 33243 was used for nuclear staining. (b, c) Quantification of activated Bax signal. Error bars 
indicate the standard deviation from three individual experiments. ***P < 0.004, **P = 0.01.Page 7 of 11
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high levels of fatty acid synthesis activity.
It has been established that cancer cells depend on an altered
cellular physiology. As an example, cancer cells favor aerobic
glycolysis instead of oxidative phosphorylation for energy pro-
duction, a phenomenon described by Warburg several dec-
ades ago [20]. Fatty acid synthesis has been proposed to
facilitate this mode of energy production in several cancer
cells [21,22]. Over-expression of PBP and NR1D1 in ERBB2-
positive breast cancer cells causes these cells to store fatty
acids at 10 times the level of other breast cancer cells (Kour-
tidis A, Carkner RD, Eifert C, Brosnan MJ, Conklin DS; unpub-
lished data) [2]. These two genes act coordinately to
upregulate de novo fatty acid synthesis, enabling ERBB2-pos-
itive cells to regenerate their NAD+ by consuming nicotinamide
adenine dinucleotide phosphate (NADPH) that is necessary
for fatty acid synthesis. As a result, the cells can continue to
catabolize glucose and maintain their metabolic balance
(Kourtidis A, Carkner RD, Eifert C, Brosnan MJ, Conklin DS;
unpublished data). ERBB2 has been also shown to have a
positive bidirectional relationship with FASN, in this way influ-
encing de novo fatty acid synthesis [23]. The tight genetic link-
age between PBP, NR1D1, and ERBB2 on the 17q12-21
Figure 4
PPARγ inhibition and palmitate treatment result in increased ROS. (a) BT474, MDA-MB-361, MCF-7, and human mammary epithelial cell (HMEC) 
cells were treated with 500 or 750 μmol/l palmitate, 20 μmol/l GW9662, or 500 μmol/l palmitate plus 20 μmol/l GW9662 for 72 hours and stained 
with hydroethidine (HE) for detection of O2- species. Hoechst 33243 was used for nuclear staining. (b) Quantification of HE signal of BT474, MDA-
MB-361, MCF-7, and HMEC cells treated with 250, 500 and 750 μmol/l palmitate for 72 hours. Error bars indicate the standard deviation from three 
individual experiments. (c) Quantification of HE signal of BT474, MDA-MB-361, MCF-7, and HMEC cells treated with 500 μmol/l palmitate and/or 
20 μmol/l GW9662 for 72 hours. Error bars indicate the standard deviation from three individual experiments. ***P < 0.02, **P = 0.05. PPAR, per-
oxisome proliferator-activated receptor; ROS, reactive oxygen species.Page 8 of 11
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that ERBB2-positive breast cancer cells are genetically pre-
programmed to depend on fatty acid synthesis for energy pro-
duction.
The generation of ROS and the biosynthesis of ceramide have
been proposed as possible mechanisms of lipotoxicity [4].
Increased ROS production in BT474 cells following PPARγ
inhibition, along with cell rescue after treatment with antioxi-
dants, support the notion that ROS production is the mediator
of palmitate toxicity in BT474 cells. However, inhibition of
ceramide synthesis under the same conditions resulted in only
a 27% increase in BT474 cell viability, showing that palmitate
toxicity is mainly independent of ceramide production.
Several studies have shown that supplementation of saturated
rather than unsaturated fatty acids is toxic to cells [25]. When
ERBB2-negative breast cancer cells like MDA-MB-231 were
involved, only palmitate, but not oleate, was shown to induce
apoptosis [9]. It has been proposed that this is because
unsaturated fats are more efficiently metabolized into triglycer-
ides [26] and that they can rescue cells from lipotoxicity by
channeling saturated fats like palmitate to triglyceride stores.
Nevertheless, a number of reports have indicated that the
Mediterranean diet, which is rich in the unsaturated oleate-
containing olive oil, has anti-oncogenic properties against
ERBB2-positive breast cancer [27,28]. Similar effects were
seen for other unsaturated fatty acids, like the omega-3 poly-
unsaturated docosahexaenoic acid [29] and the omega-6 pol-
yunsaturated γ-linolenic acid [30]. PPARγ inhibition in BT474
cells resulted in higher levels mainly of saturated rather than
unsaturated fats (Figure 1d,e), and we confirmed that the sat-
urated fatty acid palmitate is specifically toxic to these cells.
However, the unsaturated oleate was also increased by
PPARγ inhibition (Figure 1e), and we observed that oleate
treatment produced similar toxic effects on BT474 cells (data
not shown). This indicates that it is not the type of fatty acid
that is responsible for the toxicity in these cells, but rather the
overall high levels of fats caused by the significantly upregu-
lated de novo fatty acid synthesis. ERBB2-positive cells have
maximized their ability to store fats, and therefore additional
Figure 5
ERBB2-positive cells' sensitivity to palmitate is through ROS formation and ceramide production. (a) BT474 and MDA-MB-361 cells were treated 
with vehicle or 20 μmol/l GW9662 together with 0, 0.5, and 1 μmol/l of N-acetyl-cysteine (NAC) for 72 hours. Live cells were counted and pre-
sented as percentage of the GW9662 control. Error bars indicate the standard deviation from three individual experiments. ***P < 0.05. (b) BT474 
and MDA-MB-361 cells were treated with vehicle or 20 μmol/l GW9662 together with 0 and 10 μmol/l of the ceramide synthesis inhibitor fumonisin 
B1 for 72 hours. Live cells were counted and presented as percentage of the GW9662 control. Error bars indicate the standard deviation from three 
individual experiments. ROS, reactive oxygen species.Page 9 of 11
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store them by PPARγ inhibition, is lethal to these cells.
Excess of palmitate in ERBB2-positive cells could also feed-
back to inhibit fatty acid synthesis. It has been shown that
high-fat diet downregulates both FASN and malic enzyme 1
[31]. Both enzymes are necessary for de novo fatty acid syn-
thesis, because FASN is the enzyme that catalyzes palmitate
synthesis from acyl-coenzyme A and malonyl-coenzyme A
using NADPH, whereas malic enzyme 1 supplies FASN with
NADPH. ERBB2-positive breast cancer cells are sensitive to
inhibition of both FASN and malic enzyme 1 genes (Kourtidis
A, Carkner RD, Eifert C, Brosnan MJ, Conklin DS; unpublished
data). In this case, PPARγ activity is not only important for
detoxifiying the cells but also for securing palmitate into fat
stores, in order for FASN and malic enzyme 1 to continue to
function. Further examination is needed to confirm this hypoth-
esis and establish this feedback loop, which could provide
several missing links in the regulation of this metabolic proc-
ess and, therefore, further ways to eradicate this particularly
aggressive form of cancer.
Conclusions
The genetic linkage between NR1D1, PBP, and ERBB2
causes co-overexpression of these gene products such that
ERBB2-positive breast cancer cells are preprogrammed to
depend on fatty acid synthesis for energy production and sur-
vival. This study shows that the adipogenic transcription factor
PPARγ is critical for ERBB2-positive breast cancer cells to
convert the high levels of fatty acids that they produce into trig-
lycerides, allowing them to avert the cell death that results
from lipotoxicity. The decreased ability of ERBB2-positive cells
to accumulate fats after exogenous supplementation of palmi-
tate supports the notion that these cells have near toxic levels
of endogenously produced palmitate. Increasing palmitate lev-
els by inhibiting PPARγ or through the direct administration of
palmitate results in cell death. Endogenous palmitate toxicity
represents a genetically based property of ERBB2-positive
breast cancer that can be exploited for therapeutic interven-
tion.
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